Patent ID: 8426404

Claim:
A compound of Formula Ia: and pharmaceutically acceptable salts thereof, in which: p is selected from O and 1; n is 1-3; q is 1; R 5 is selected from hydrogen, —XNR 7 R 8 , pyrimidine-C 0-4 alkyl, pyridine-C 0-4 alkyl, phenyl, C 3-10 cycloalkyl-C 0-4 alkyl and C 3-6 heterocycloalkyl-C 0-4 alkyl; wherein said C 3-6 heterocycloalkyl is a saturated monocyclic ring system comprising the shown number of atoms, with the proviso that one or more of the shown carbon atoms is substituted by O or NR wherein R is hydrogen or C 1 -4 alkyl; R 7 and R 8 are C 1-4 alkyl; R 6 is hydrogen; or R 5 and R 6 together with the nitrogen to which R 5 and R 6 are both attached form morpholine or piperidine; wherein any pyrimidine-C 0-4 alkyl, pyridine-C 0-4 alkyl or C 3-10 cycloalkyl-C 0-4 alkyl of R 5 , or the combination of R 5 and R 6 can be optionally substituted with 1 to 2 radicals independently selected from —XNR 7 R 8 and —XOR; said phenyl of R 5 is substituted with —XR 9 ; said C 3-6 heterocycloalkyl-C 0-4 alkyl of R 5 is optionally substituted with —XOR; wherein X is a bond or C 1-4 alkylene; R 7 and R 8 are independently selected from hydrogen and C 1-4 alkyl; and R 9 is C 3-10 heterocycloalkyl, which is a saturated monocyclic ring system comprising the shown number of atoms, with the proviso that one or more of the shown carbon atoms is substituted by O or NR wherein R is as described above; R 10 is hydrogen; R 15 is selected from halo, C 1-6 alkyl and C 1-6 alkoxy; and R 16 is selected from halo, methoxy, nitro, —NR 12 C(O)R 13 , —C(O)NR 12 R 12 , —NR 12 R 12 , —C(O)OR 12 and —C(O)NR 12 R 13 ; wherein each R 12 is independently selected from hydrogen and C 1-6 alkyl; R 13 is selected from phenyl, thienyl, pyrazolyl, pyridinyl or isoxazolyl; wherein any phenyl, thienyl, pyrazolyl, pyridinyl or isoxazolyl substituent of R 13 is optionally substituted by 1 to 2 radicals independently selected from halo, C 1-6 alkyl, halo-substituted-C 1-6 alkyl, imidazole-C 0-4 -alkyl, C 3-10 cycloalkyl, C 3-10 heterocycloalkylC 0-4 alkoxy and C 3-10 heterocycloalkyl-C 0-4 alkyl; wherein said C 3-10 heterocycloalkyl-C 0-4 alkoxy and C 340 heterocycloalkyl-C 0-4 alkyl are each a saturated monocyclic ring system comprising the shown amount of atoms with the proviso that one or more of the shown carbon atoms is substituted by O or NR wherein R is as described above; and said C 3-10 heterocycloalkyl-C 0-4 alkoxy and C 3-10 heterocycloalkyl-C 0-4 alkyl are each optionally substituted by 1 radical independently selected from C 1-6 alkyl, hydroxyl-substituted-C 1-6 alkyl and NR 7 R 8 , wherein R 7 and R 8 are as described above.